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Abstract: Infections with the nine human herpesviruses (HHVs) are globally prevalent and characterized
by lifelong persistence. Reactivations can potentially manifest as life-threatening conditions for which
the demonstration of viral DNA is essential. In the present study, we developed HERQ-9, a pan-HHV
quantitative PCR designed in triplex reactions to differentiate and quantify each of the HHV-DNAs: (i)
herpes simplex viruses 1 and 2 and varicella-zoster virus; (ii) Epstein-Barr virus, human cytomegalovirus,
and Kaposi’s sarcoma-associated herpesvirus; and (iii) HHV-6A, -6B, and -7. The method was validated
with prequantified reference standards as well as with mucocutaneous swabs and cerebrospinal fluid,
plasma, and tonsillar tissue samples. Our findings highlight the value of multiplexing in the diagnosis of
many unsuspected, yet clinically relevant, herpesviruses. In addition, we report here frequent HHV-DNA
co-occurrences in clinical samples, including some previously unknown. HERQ-9 exhibited high specificity
and sensitivity (LOD95s of ฀10 to ฀17 copies/reaction), with a dynamic range of 101 to 106 copies/฀l.
Moreover, it performed accurately in the coamplification of both high- and low-abundance targets in the
same reaction. In conclusion, we demonstrated that HERQ-9 is suitable for the diagnosis of a plethora
of herpesvirus-related diseases. Besides its significance to clinical management, the method is valuable
for the assessment of hitherto-unexplored synergistic effects of herpesvirus coinfections. Furthermore, its
high sensitivity enables studies on the human virome, often dealing with minute quantities of persisting
HHVs.
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Abstract  24 
 25 
Infections with the nine human herpesviruses (HHVs) are globally prevalent and 26 
characterized by life-long persistence. Reactivations can potentially manifest as life-27 
threatening conditions for which the demonstration of viral DNA is essential. 28 
In the present study, we developed HERQ-9, a pan-HHV qPCR designed in triplex reactions 29 
to differentiate and quantify each of the HHV-DNAs: 1) HSV-1&2, VZV; 2) EBV, HCMV, 30 
KSHV; and 3) HHV-6A/B-7. The method was validated with pre-quantified reference 31 
standards as well as with mucocutaneous swabs, cerebrospinal fluid, plasma and tonsillar 32 
tissue samples.  33 
Our findings highlight the value of multiplexing in the diagnosis of many unsuspected, yet 34 
clinically relevant, herpesviruses. In addition, we report here frequent HHV-DNA co-35 
occurrences in clinical samples, including some previously unknown. 36 
HERQ-9 exhibited high specificity and sensitivity (LOD95s of  ~10 - ~17 copies/reaction) with 37 
a dynamic range of 101 to 106 copies/l. Moreover, it performed accurately in the co-38 
amplification of both high and low abundance targets in the same reaction. 39 
We demonstrated that HERQ-9 is suitable for the diagnosis of a plethora of herpesvirus-40 
related diseases. Besides its significance to clinical management, the method is valuable for 41 
the assessment of hitherto unexplored synergistic effects of herpesvirus co-infections. 42 
Furthermore, its high sensitivity enables studies on the human virome, often dealing with 43 
minute quantities of persisting HHVs.  44 
  45 
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The importance  46 
 47 
By adulthood, almost all humans become infected by at least one herpesvirus (HHV). The 48 
maladies inflicted by these microbes extend beyond the initial infection as they remain inside 49 
our cells for life and can reactivate, causing severe diseases. The diagnosis of active 50 
infection by these ubiquitous pathogens includes the detection of DNA with sensitive and 51 
specific assays. We developed the first quantitative polymerase chain reaction assay 52 
(HERQ-9) designed to identify and quantify each of the nine human herpesviruses. The 53 
simultaneous detection of HHVs in the same sample is important since they may act together 54 
to induce life-threatening conditions. Moreover, the high sensitivity of our method is of 55 
extreme value for assessment of the effects of these viruses persisting in our body and their 56 
long-term consequences on our health.  57 





The nine human herpesviruses (HHVs) are ubiquitous pathogens that persist life-long after 61 
primary infection. HHVs cause many disorders ranging from mild mucocutaneous diseases to 62 
severe central nervous conditions, birth defects and cancer. Their ability to reactivate poses 63 
significant risks, particularly to immunosuppressed patients, such as transplant recipients, in 64 
whom Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), HHV-6B and Kaposi's 65 
sarcoma-associated herpesvirus (KSHV) can induce life-threatening conditions (1–8). 66 
The investigation of active HHV infections includes, among other markers, the detection of 67 
viral nucleic acids, typically by quantitative polymerase chain reaction (qPCR). In addition, 68 
the simultaneous detection of these pathogens has been shown to be beneficial as their 69 
recognition may be difficult based on the clinical presentation alone (9–15).  70 
While several multiplex qPCRs have been introduced for detection of HHVs (16–19), none 71 
are designed to quantify them all. In addition, only few of the existing protocols distinguish 72 
between the closely related HHV-6A and HHV-6B, a distinction that may be crucial as the 73 
former still lacks clear association to disease (20–23).  74 
In the present study, we developed a pan-herpes multiplex assay, HERQ-9, that quantifies 75 
and discriminates each of the HHVs using three separate triplex-qPCR reactions: the first 76 
amplifies herpes simplex virus types 1&2 (HSV-1&2) and varicella-zoster virus (VZV), the 77 
second EBV, HCMV and KSHV, and the third HHV-6A, 6B and 7. We validated our assay 78 
using pre-quantified reference materials and evaluated its performance with various clinical 79 
samples as well as solid tissue material. 80 
HERQ-9 simplifies diagnosis and improves the clinical management and risk assessment of 81 
highly susceptible populations (1, 5, 8, 24–26). Moreover, its high sensitivity is of significant 82 






In silico evaluation of amplicons, primers and probes 87 
The designed primers and probes were queried against all available sequences (full or partial 88 
genomes) in the NCBI database. The oligonucleotides showed perfect match for the different 89 
strains except for four sequences of HHV-6A (KY316054.1, KT3555575.1, KY316056.1, 90 
KY316047.1) and two of HCMV (KY490070.1, KP745685.1) for which one to two 91 
mismatches were observed far from the 3’-end. 92 
We found no unspecific binding to other viruses or human DNA except for the primers and 93 
probe of HSV-2 that had also complete homology to chimpanzee alpha-1 herpesvirus 94 
(JQ360576.1).  95 
In silico analysis of amplicons, primers and probes revealed no relevant secondary 96 
structures, primer-dimers or cross-dimers (see Fig. S1 and S2 in the supplemental material).  97 
Analytical sensitivities and specificities 98 
 99 
We evaluated the sensitivities using eight replicates of the respective plasmids in seven 100 
dilutions ranging from 50 to 1 copies per reaction. Based on probit link function, the limits of 101 
detection (LOD95)  of HERQ-9 for HSV-1, HSV-2, VZV, EBV, HCMV, KSHV, HHV-6A, HHV-102 
6B and HHV-7 were respectively 12, 13, 13, 10, 16, 17, 11, 11 and 11 copies per reaction. 103 
The values were similar in singleplex format (see Fig. S3 in the supplemental material). 104 
The multiplex assay detected all HHVs correctly from infected cell lines without cross-105 
amplification of other HHVs, human DNA or near-full/full-length genomes of B19V, 106 
polyomaviruses BKV, JCV and MCV. All the no-template water controls remained negative 107 
throughout the PCR analyses. 108 




We tested the intra- and interassay variations in three separate qPCR runs using five 111 
replicates of the individual HHV plasmids (106 – 101 copies /µl) and plasmid mixes pMIXI 112 
(HSV-1,2;VZV), pMIXII (EBV, HCMV, KSHV) and pMIXIII (HHV-6A,B; 7).  113 
The assay showed excellent short-term repeatability and long-term reproducibility in both 114 
singleplex and multiplex formats as well as with the pMIXI-III. The highest standard 115 
deviations in Cq values (intraassay) and coefficients of variation between runs (interassay) 116 
were seen at the lowest template copies (Tables 1 & 2). 117 
The method was linear in the range of 101 to 106 copies per µl and the qPCR efficiencies 118 
were between 95.9% and 103.8% in all the experiments.  119 
The HHV plasmid dilutions spiked with 500ng of human DNA (HaCaT cells) showed equal 120 
linearity to pure HHV plasmids (Fig. 1, see also Fig. S4 in the supplemental material). 121 
Comparison to pre-quantified reference samples. 122 
 123 
We correlated the quantification of HERQ-9 to several pre-quantified reference materials. 124 
The results are summarized in Table 3. 125 
Each of the two strains of HSV-1 and HSV-2 DNA had spectrophotometrically estimated 126 
quantities of 4.3E9 and 6.1E9 copies/µl and 1.9E9 and 3.8E9 copies/µl, respectively. The 127 
calculated loads by our multiplex qPCR were 4.2E9 and 6.1E9 copies/µl for HSV-1, and 128 
9.1E8 and 1.9E9 copies/µl for HSV-2. The conversion factors were hence 0.99 (HSV-1) and 129 
0.49 (HSV-2).  130 
A VZV-DNA extract (ATCC) containing 5.6E5 copies/µl was calculated to have 1.8E6 131 
copies/µl by HERQ-9 with a conversion factor of 3.2.  132 
EBV, HCVM and HHV-6B WHO international standards contained 1.0E4, 1.0E4 and 1.1E5 133 
IU/µl, respectively. The calculated copies by HERQ-9 were 1.0E4 copies/µl for EBV, 3.2E4 134 
copies/µl for HCMV and 1.8E5 copies/µl for HHV-6B. Hence, the conversion factors 135 
(copies/IU) were 1.0, 3.2 and 1.6, respectively.  136 
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Spectrophotometrically estimated copies of KSHV DNA were 2.2E9 copies/µl and calculated 137 
to be 5.0E9 copies/µl with our assay, yielding a conversion factor of 2.3. 138 
HERQ-9 showed good correlation with HHV-6A, HHV-6B and HHV-7 spiked in sera (Fig. 2). 139 
The conversion factors were 1.1, 1.3 and 6.8, respectively.  140 
Analysis of clinical samples 141 
We tested several types of clinical samples and compared the positive and negative 142 
agreements against reference methods. A summary of the results is presented in Table 4. 143 
Plasma  144 
We tested 60 plasma samples, previously studied for EBV and/or HCMV at Turku University 145 
Hospital. 146 
Altogether 13/13 and 16/16 plasma samples positive for EBV and HCMV by a reference 147 
qPCR, respectively, were positive by HERQ-9 with good correlation in viral loads (Fig. 3). 148 
Seven out of nine samples reported as borderline for EBV by the clinical laboratory (50-200 149 
copies/ml of plasma) were positive in the new assay, as were four of five HCMV-borderline 150 
samples (50-200 copies/ml of plasma). Furthermore, the new qPCR found additional 151 
samples positive for EBV (n=3) and HCMV (n=5) that in the hospital laboratory had been 152 
tested only for either of the virus. These samples were re-analyzed with a reference qPCR 153 
confirming one EBV and three HCMV positivities.  154 
Furthermore, among the 60 plasma samples studied with HERQ-9, six were positive for 155 
HHV-6B (median 2.7E2 copies/ml of plasma, range 1.7E2-5.2E3); one for HHV-6A (6.3E2 156 
copies/ml of plasma); and five for HSV-1 (median 1.2E4 copies/ml of plasma, range 8.0E2 - 157 
5.1E4). The co-occurrence of HHVs in plasma was seen in 14 patients of whom three had 158 
EBV/HCMV/HSV-1; one EBV/ HCMV/HHV-6B; one EBV/HHV-6B/HSV-1; five EBV/HCMV; 159 
two EBV/HHV-6B; one HCMV/HHV-6B; and one EBV/HSV-1 (Fig. 4A). 160 
Mucocutaneous swabs  161 
We tested 114 mucocutaneous swab samples previously investigated for HSV-1&2 or VZV at 162 
Turku University Hospital. 163 
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HERQ-9 identified correctly all the mucocutaneous swab samples that had tested positive by 164 
rapid viral culture for HSV-1 (n=35, median 5.6E7, range 1.4E5 to 8.2E9 copies/ml of 165 
collection media) and HSV-2 (n=30, median 3.3E7, range 2.9E5 to 3.5E8 copies/ml of 166 
collection media). In contrast, the 15 culture-negative controls showed no amplification for 167 
HSV-1 or HSV-2. However, two of these negative samples were positive instead for VZV, at 168 
2.0E7 and 3.2E4 copies/ml of collection media and were confirmed to be VZV-DNA positive 169 
with a control PCR (4, 31). In addition, 5/5 HSV-1 and 4/4 HSV-2 positive DNA extracts 170 
previously tested by a reference PCR (4, 31) were also positive with HERQ-9. 171 
All the VZV samples positive (n=15) by enzyme immunoassay (EIA) were positive with the 172 
new assay, at median quantities of 4.5E7 copies/ml of collection media (range 8.0E6 to 173 
2.7E9). On the other hand, among 10 VZV antigen-negative samples, two contained VZV 174 
DNA at 3.6E6 and 4.7E3 copies/ml of collection media. Of these, the former was confirmed to 175 
be VZV DNA positive by the reference PCR. Incidentally, among the remaining eight 176 
samples negative for the VZV antigen, three showed positivity for HSV-1 instead, at loads of 177 
7.7E7, 7.2E7 and 6.3E1 copies/ml of collection media. Only the two samples with the highest 178 
copy numbers were confirmed to be positive for HSV-1 DNA by the control PCR.  179 
Moreover, we co-detected other HHVs in these mucocutaneous swabs (Fig. 4C and 4D). Of 180 
the HSV-1 positive samples, 20.9% were also positive for EBV-DNA, 4.7% for HCMV-DNA, 181 
9.3% for HHV-7 DNA and 2.3% for HHV-6B DNA. Among the HSV-2 positive swabs, 5.3% 182 
were also positive for EBV, 8.8% for HCMV, and 2.9% for HHV-7. From 19 VZV positive 183 
swabs, one was positive for EBV-DNA (5.3%). Of all the 114 swabs, two were quadruple 184 
positive (HSV-1/EBV/HCMV/HHV-7 and HSV-2/EBV/HCMV/HHV-7) and four were triple 185 
positive (HSV-1/EBV/HCMV, HSV-1/HHV-6B/HHV-7 and two HSV-2/EBV/HCMV). The copy 186 
numbers of the other co-detected HHVs (generally log2-log3 copies/ml of collection media) 187 
were always lower than those for HSV-1, HSV-2 or VZV. However, a few samples had log5-188 
log6 copies/ml of EBV DNA. Of all the mucocutaneous swab samples negative for HSV-1, 189 
HSV-2 and VZV (n=18), one (5.6%) tested positive for EBV DNA. 190 
Cerebrospinal fluid (CSF) 191 
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Eight CSF samples were analyzed with the pan-herpes multiplex assay. Two were positive 192 
for VZV (3.23E3 and 1.64E5 copies/ml of CSF) in concordance with the hospital laboratory 193 
reference PCR (4, 31).  194 
HHV prevalences in tonsillar tissue. 195 
 196 
The HHV DNA prevalences in 35 tonsillar tissue samples were 80% for HHV-7, 71% for EBV, 197 
66% for HHV-6B, 3% for HSV-1 and 3% for HCMV. No HSV-2, VZV or KSHV were found 198 
(Fig. 5). From these samples, two were positive for four HHVs, 17 for three, 10 for two, while 199 
four tonsils were negative for all the HHVs (Fig. 4B). The median viral loads (copies/million 200 
cells) were highest for EBV (2.1E2, IQR 9.6E2), followed by HHV-7 (3.6E1, IQR 1.3E2) and 201 
HHV-6B (1.1E1, IQR 2.2E1). 202 
Co-quantification of mixed high- and low-abundance targets 203 
 204 
We tested uneven copies of whole HHV genomes in the same reaction (range 4.5E0 to 205 
1.1E6 copies/µl) and found that all the viruses were correctly differentiated and accurately 206 
quantified by HERQ-9 (Pearson correlation coefficient r = 0.996, p<0.01). Higher coefficients 207 
of variation were seen at lower viral copies (Table 5).   208 
Discussion 209 
 210 
Our newly developed pan-herpes multiplex-qPCR assay, HERQ-9, outstands for its ability to 211 
differentiate and quantify the genomes of all nine human herpesviruses.  212 
HERQ-9 was designed on three distinct triplex-qPCR reactions to meet, on the one hand, the 213 
clinical needs and, on the other, the technical constraints inherent to PCR multiplexing. 214 
Indeed, the capacity to co-detect several targets is restricted by the spectral overlap of 215 
different fluorophores as well as the number of channels in the qPCR instrument (maximum 216 
of six) (32). Moreover, a greater number of targets can increase cross-reactions between 217 
primers and probes, hampering assay performance. 218 
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The new multiplex assay performed remarkably well on cell, plasma, CSF and 219 
mucocutaneous swabs as well as on palatine tonsils. HHV genoprevalences in this lymphoid 220 
organ have been reported to be highest for EBV (20.4 – 88.8%), followed by HHV-7 (71.4%), 221 
HHV-6B (50.7%), HCMV (0-5.4%) and HSV-1 (1.8-6.3%) (33–35), in line with our results. In 222 
addition, we frequently co-detected several HHVs in the same tonsil, a phenomenon only 223 
previously reported by Berger et al. in young children (36). 224 
HERQ-9 had good agreement with reference materials. The observed dissimilarities were 225 
likely to be related to the types and sensitivities of different methodologies (e.g., viral culture, 226 
EIA, spectrophotometry), sample processing (e.g., DNA extraction methods), as well as the 227 
design of the PCR methods compared. Regarding the latter, the primer and probe design, 228 
amplicon size, target gene and its polymorphisms, reagents and standards can all account 229 
for disagreements between qPCRs (37–39). In fact, these discrepancies have urged the 230 
introduction of WHO international standards for EBV, HCMV and HHV-6B to increase the 231 
commutability between assays (39–42). However, this has had only relative value since, 232 
even after standardization, the inter-laboratory variabilities continue to be high (up to 1.5 log10 233 
IU/ml on average) (39, 42).  234 
Our findings emphasize the importance of multiplexing for comprehensive diagnosis and 235 
clinical management. Indeed, we identified additional HHVs in clinical samples that had been 236 
tested only for a single pathogen, encountering several unforeseen HSV-1 or VZV findings in 237 
mucocutaneous swabs, as well as EBV-HCMV co-reactivations in plasma of immunodeficient 238 
patients. In addition, we co-detected other HHVs in plasma in several combinations 239 
(EBV/HSV-1, EBV/HHV-6B, HCMV/HHV-6B  EBV/HCMV/HSV-1, EBV/HCMV/HHV-6B and 240 
EBV/HHV-6B/HSV-1). These coincidental discoveries, also noted by others (4, 19, 43), may 241 
have a significant impact on risk assessment and prognosis. Indeed, HHVs are thought to 242 
individually or synergistically contribute to viral syndromes (5, 8, 44), organ rejection (19) or 243 
the development of cancer (45, 46). 244 
Moreover, we found other HHVs besides HSV-1, HSV-2 or VZV in mucocutaneous lesions 245 
(up to four in the same sample). The most common were EBV, HCMV and HHV-7, whose 246 
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low viral loads were likely to represent skin virome (47) or latency in mobilized leukocytes 247 
(48). Yet, in a few samples, EBV-DNA levels approached those of HSV-1 or HSV-2, 248 
suggestive of in-situ co-reactivation or -infection. Our detection of both EBV and HSV-1 in 249 
mucocutaneous lesions and plasma supports an interplay between these two viruses, as has 250 
been shown in vitro by Wu et al. (49). To the best of our knowledge, we are the first to report 251 
on HHV co-occurrences in classical herpetic lesions.  252 
In conclusion, we demonstrated that HERQ-9 is suitable for the diagnosis of a plethora of 253 
herpesvirus-related diseases. Besides its significance for clinical management, the high 254 
sensitivity and specificity of this method will be of particular value for studies of the human 255 
virome generally dealing with minute quantities of persisting HHVs. 256 
 257 




Sequences of the reference strain (90-336 bp), including the corresponding qPCR amplicon, 262 
were inserted into a pIDTSmart backbone (Integrated DNA technologies). The plasmids  263 
(pHSV-1, pHSV-2 and pVZV; pHHV-6A, pHHV-6B, pHHV-7, pEBV, pHCMV and pKSHV) 264 
were transformed into E.coli, extracted (see DNA extraction) and confirmed with restriction 265 
analysis to contain the correct insert (for whole insert sequences, see Text S1 in the 266 
supplemental material). The concentrations were measured spectrophotometrically, and the 267 
plasmids (diluted serially from 106 to 101 copies/µl in 10mM TE-buffer) were stored at -80°C. 268 
In addition to single-plasmid analysis, triple-plasmid combinations were made: pHSV-1, 269 




Plasmids containing full/near-full length genome of parvovirus B19 genotype 1 (50) and 272 
polyomaviruses BKV (NC_001538), JCV (NC_001699) (generous gifts from Dr. Eeva 273 
Auvinen)  and MCV (inserted in vector backbone pJ241, a gift from Patrick Moore (51); 274 
Addgene plasmid # 32059) were used to test unspecific amplification.  275 
 276 
Infected cell cultures 277 
Primers and probes were initially tested using viral DNA extracted from virus-infected cell 278 
cultures. HSV-1 (strain F), HSV-2 (strain G) and VZV (strain Ellen) were propagated in 279 
HaCat, human foreskin fibroblast and Vero cells; EBV in Raji cells; HCMV (strain AD169) in 280 
human lung fibroblast MRC-5, HHV6A (strain GS) in HSB-2 cells, HHV6B (strain Z29) in 281 
MOLT-3 cells,  HHV7 (strain JI) in SupT-1 cells and KSHV (strain rKSHV.219) in latent and 282 
lytic iSLK.219 cells. (52) 283 
Uninfected HaCaT cells were used for human DNA spiking experiments.  284 
Pre-quantified reference material 285 
 286 
All the reference materials are presented in Tables 3 & 4. 287 
Cell-free viral nucleocapsids 288 
HSV-1 and HSV-2 nucleocapsids were isolated from pseudonymized dermal or mucosal 289 
lesion samples at the virus diagnostic unit of Turku University Hospital. The viruses were 290 
initially typed by a rapid viral culture immunoperoxidase assay (53) and confirmed by HSV 291 
type-specific gD (US6) gene-based PCR (54). For viral nucleocapsid DNA preparations, low-292 
passage stocks were generated in Vero cells (African green monkey kidney; ATCC), and the 293 
viral genomic DNA was prepared as described (55, 56) (see Text S2 in the supplemental 294 
material for more detailed description). Two strains of HSV-1 (HSV-H1211 and HSV-H1215) 295 
and HSV-2 (HSV2-H12211 and HSV2-H1526) were prepared and the viral copies 296 
determined spectrophotometrically to be used as reference standards in dilutions 1:10 000 297 
and 1:100 000. 298 
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WHO international standards 299 
WHO international standards for EBV, HCMV and HHV-6B (NIBSC codes 09/260, 09/162 300 
and 15/266, respectively) (57–59) were tested undiluted and in dilutions 1:10 and 1:100 with 301 
HERQ-9, to obtain conversion factors (viral DNA copies/International units). 302 
KSHV genome in bacterial artificial chromosome (BAC) 303 
KSHV-BAC16 DNA (a generous gift by prof. Carolina Arias, UCSB, CA, USA), derived from 304 
the KSHV strain of JSC-1 primary effusion lymphoma (PEL) cell line, was purified from E. coli 305 
(60). The viral copy numbers were estimated spectrophotometrically. This reference was 306 
analyzed in dilutions 1:10 000, 1:100 000 and 1:1000 000 with the multiplex assay.  307 
 308 
Spiked sera 309 
Serum samples spiked with HHV-6A (n=15) or HHV-6B (n=15) (4 x 106 to 4 x 102 copies/ml 310 
of sera), and HHV-7 (n=12) were obtained from the HHV-6 Foundation (Santa Barbara, 311 
California, USA). Reference copy numbers given by the providing institute were used for 312 
HHV-6A and HHV-6B (59), while the HHV-7 DNA was quantified with a commercial HHV-7 313 
qPCR kit (PCRmax) in our laboratory. 314 
 315 
ATCC standard 316 
Quantitative Genomic DNA of VZV (ATCC® VR1367DQ ™) was analyzed with HERQ-9 317 
undiluted and at 1:10 and 1:100 dilutions. 318 
Clinical samples 319 
All the clinical HHV samples were collected at the virus diagnostic unit of Turku University 320 
Hospital, and are presented in Table 5. These included: 80 mucocutaneous swab samples of 321 
which 35 were positive for HSV-1 and 30 for HSV-2 by rapid viral culture immunoperoxidase 322 
assay (53); 25 mucocutaneous swab samples of which 15 were positive for VZV by antigen 323 
enzyme immunoassay (61); five HSV-1 and four HSV-2 PCR positive DNA extracts from 324 
mucocutaneous swab samples tested by a reference PCR (4, 31); and eight CSF samples of 325 
which two were VZV positive by a control PCR (4, 31).  326 
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In addition, 60 plasma samples were investigated of which 17 had been studied only for EBV 327 
(GeneProof Epstein-Barr Virus (EBV) PCR Kit), 17 only for HCMV (GeneProof 328 
Cytomegalovirus (CMV) PCR Kit) and 26 for both. From these 13 and 16 samples were 329 
reported as EBV and HCMV positive (>200 copies/ml of plasma), respectively, while nine 330 
and five had borderline copy numbers (50-200 copies/ml of plasma). 331 
Tonsillar tissues 332 
Altogether 35 mechanically homogenized tonsillar tissues were screened for the nine HHVs. 333 
The patients were 2 to 69 years of age (mean, 26), with eight <12 years (48). The viral loads 334 
were normalized per 106 cells, determined with the human single-copy gene RNase P-qPCR 335 
(48). 336 
Herpesvirus DNA mixes 337 
Mixtures of three viral genomes extracted from the previously mentioned infected cell lysates 338 
[i) HSV-1, HSV-2 and VZV; ii) EBV, HCMV and KSHV] or spiked serum [iii) HHV-6A, 6B and 339 
7] were tested at uneven quantities, ranging from 4.5E0 to 1.1E6 copies/l of DNA extract. 340 
Primers and hydrolysis probes 341 
Primers and probes were designed for all HHVs, except for EBV (62). For each virus, several 342 
primer pairs were constructed in silico, in conserved genes (16, 18, 63, 64). Degenerate 343 
primers were designed for HCMV to cover polymorphisms in the target area. Moreover, for 344 
HHV-6A, two probes were custom-designed to contain six locked nucleic acids (LNA) each 345 
(for shorter probe length), and a single-nucleotide difference for specific binding to different 346 
strains (Table 6).  347 
The tendency of primers and probes to form secondary structures, primer dimers and cross-348 
dimers was evaluated with Multiple Primer Analyzer (Thermo Fisher Scientific), while the 349 
propensity of the amplicons to form secondary structures was checked with Mfold Web 350 
Server. A BLAST search (65) was performed to confirm primer binding to each of the virus 351 
strains in the nucleotide collection database (NCBI).  352 
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Primer candidates designed in silico were tested at 200 nM concentration with plasmid 353 
dilutions (see Plasmids), human DNA (HaCaT 500 ng/reaction) and nuclease-free water in a 354 
SYBR green format (Maxima SYBR Green qPCR master mix, Thermo Fisher Scientific) 355 
followed by melting curve analysis. Primer pairs showing the highest efficiency and sensitivity 356 
with no primer dimer formation were chosen for further testing with the hydrolysis probes. 357 
Concentrations of the primer pairs were optimized empirically with a matrix of reactions 358 
ranging from 100 nM to 600 nM. The probes were tested in a 100 nM to 400 nM range. The 359 
final primer and probe concentrations are presented in Table 6.  360 
Primers and hydrolysis probes were purchased as HPLC purified except for two 361 
degenerative primers (HCMV), which were cartridge purified (Sigma Aldrich). For the triplex 362 
reactions, the probes were labeled with 6-FAM-BHQ-1, JOE-BHQ-1 and TxRd-BHQ-2.  363 
Quantitative PCR protocol 364 
Four commercial master mixes were pre-tested with HSV-1, HSV-2 and VZV plasmids and 365 
viral genomes with special consideration given to the performance in the presence of human 366 
DNA and the co-amplification of markedly low and high-abundance targets. Consequently, 367 
TaqPath ProAmp Multiplex Master Mix (Thermo Fisher Scientific) was chosen for the 368 
multiplex assay. 369 
The qPCR thermal profile comprised initial denaturation at 95 oC for 10 min followed by 45 370 
cycles of 15 s at 95 oC and 60 s at 60 oC. The qPCR reactions contained 5 l of template, 2X 371 
TaqPath ProAmp Multiplex Master Mix, primers and probes (Table 6), and nuclease-free 372 
water in a final volume of 20 l. Water was used as negative control in all the qPCR runs. 373 
The samples were run in duplicate in AriaMx Real-time PCR System (Agilent) and analyzed 374 
with the Aria Real-Time PCR Software (v. 1.3) provided by the manufacturer. The adaptive 375 
fluorescence baseline, efficiency, slope, R2-values and intercept were calculated by the 376 
software. Background-based threshold was set for cycles 5 to 9 for the FAM and TexasRed 377 
dyes, and 8 to 11 for the JOE dye. 378 
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Pre-testing of primers in SYBR green format consisted of the above-mentioned thermal 379 
profile, followed by a melting curve analysis at 95 oC for 10 min, 45 oC for 30 s and 95 oC for 380 
30 s. The melting curve analysis was performed with a resolution of 0.5 oC and soak time of 381 
5 s. 382 
DNA extraction 383 
DNA from plasma, mucocutaneous swabs, CSF and WHO international standards were 384 
extracted from 200 l of starting material with the QIAamp DNA Blood Mini Kit (Qiagen); DNA 385 
from cells and virus-infected cell lines with the QIAamp DNA mini kit (Qiagen); DNA from 386 
KSHV BAC with NucleoBond® Xtra Midi EF kit (Macherey-Nagel); and transformed plasmids 387 
with GeneJET Plasmid Miniprep kit (Thermo Fisher Scientific), according to manufacturer 388 
instructions. The final elution volumes were 100 l (with the exception of 50 l for plasma and 389 
60 l for CSF samples). In every extraction, at least two negative controls (phosphate-390 
buffered saline) were included. 391 
 392 
Analytical sensitivity and specificity 393 
The analytical sensitivities were determined in singleplex and multiplex formats using eight 394 
replicates of each HHV plasmid template in 50, 25, 15, 10, 5, 3  and 1 copies per reaction. 395 
The proportion of positive results was fit into a generalized linear model using probit link 396 
function (MATLAB v.R2018b) to approximate the limit of detection (LOD95) for a given target. 397 
The analytical specificities were evaluated by cross-testing: a) 107 copies of viral genomic 398 
DNA extracted from infected cell lysates and plasmid constructs of each HHV; b) Plasmids 399 
containing near full/full-length genomes of polyomaviruses BKV, JCV and MCV; and 400 
parvovirus B19 genotype 1. In addition, 1000 ng of cellular DNA extracted from HaCaT cells 401 




Repeatability and reproducibility 404 
The intra- and interassay variations were calculated using three separate qPCR runs using 405 
five replicates of i) HHV plasmids (106 – 101 copies /µl) in singleplex and multiplex formats 406 
and ii) plasmid mixes pMIXI, pMIXII, pMIXIII (106 – 101 copies /µl) in multiplex format. Two of 407 
the replicates were used to generate a standard curve and three were marked as unknowns. 408 
The standard deviations of the Cq values of the five replicates were used as a measure of 409 
intraassay variation. A coefficient of variation calculated from the copy numbers of unknown 410 
replicates from three separate runs was used to estimate the interassay variation. 411 
Statistical analysis  412 
Boxplots were built with Rstudio (v.1.2.5001) and Excel 2016 (v.16.0.4964.1000) was used to 413 
create scatterplot graphs. Pearson correlation coefficient between estimated and quantified 414 
copies in virus mixes was calculated with SPSS (v.25). Venn diagrams were made with 415 
InteractiVenn (66). 416 
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Figure Legends 674 
 675 
Figure 1. A) Amplification and standard curves of HSV-1 plasmid dilutions from 106 to 101 676 
copies/µl in singleplex (Red), multiplex (Green) and together with HSV-2 and VZV plasmids 677 
(pMIXI) in the same mix (Blue). (B) pMIXI dilution series spiked with 500 ng/reaction of 678 
human DNA (HaCaT cells). The y-axis represents baseline-corrected fluorescence signal 679 
(amplification curve) or cycles (standard curve). The x-axis represents cycle number 680 
(amplification curve) or plasmid copies in reaction(log10) (standard curve). Analogous 681 
illustrations for other herpesviruses can be found in Fig. S4. 682 
Figure 2. Reference copy numbers of (A) HHV-6A (B) HHV-6B (C) HHV-7  spiked sera 683 
plotted against copy numbers quantified by HERQ-9. Viral DNA copy numbers are presented 684 
per ml of serum (log10  transformed). R
2 indicates the coefficient of determination between the 685 
copy numbers. 686 
Figure 3. Comparison of (A) EBV and (B) HCMV quantities (copies/ml of plasma in log10)  as 687 
determined by HERQ-9 and GeneProof EBV and CMV PCR kit –reference assays.  688 
Figure 4. A Venn diagram representing HHV co-occurrence in (A) 60 plasma samples, (B) 689 
35 palatine tonsils, (C) 43 HSV-1 positive mucocutaneous swab samples and (D) 34 HSV-2 690 
positive mucocutaneous swab samples; n = number of positive cases. 691 
Figure 5. HHV-6B, HHV-7, EBV, HSV-1 and HCMV copies per million cells. Notches 692 
represent IQR (interquartile range) of the samples and whiskers range +/- 1.5 IQRs from the 693 
upper and lower quartiles. 694 
 695 
Figure S1. Primer dimers, cross-dimers and secondary structures analysis of the primers 696 
and probes with Multiple Primer Analyzer (Thermo Fisher Scientific). The sensitivity of three 697 
was used with a primer concentration of 0.5 µM and a salt concentration of 50 mM. 698 
25 
 
Figure S2. Amplicon secondary structure analyzed with Mfold Web Server. The reaction 699 
temperature was set to 60°C, [Na+] to 50mM, [Mg++] to 3.0 mM and other settings left as 700 
default. The green nucleotides represent probe binding areas. 701 
Figure S3. Probit link function estimating LOD95 of qPCRs in singleplex and multiplex 702 
formats. The proportion of positives from eight plasmid replicates at 50, 25, 15, 10, 5, 3 and 1 703 
copies/reaction was fit into the model to approximate the assay sensitivity. 704 
Figure S4. Amplification and standard curves in 106 to 101 copies/µl of plasmid dilutions of 705 
HSV-2 (A) and (B), VZV (C) and (D), EBV (E) and (F), HCMV (G) and (H), KSHV (I) and (J), 706 
HHV-6A (K) and (L), HHV-6B (M) and (N), HHV-7 (O) and (P). On the left are represented 707 
plasmids in singleplex (Red), multiplex (Green) and pMIXI-III (Blue). On the right, pMIXI-III 708 
dilution series spiked with 500 ng/reaction of human DNA (HaCaT cells). The y-axis 709 
represents baseline-corrected fluorescence signal (amplification curve) or cycles (standard 710 
curve). The x-axis represent cycle number (amplification curve) or plasmid copies in 711 
reaction(log10) (standard curve). 712 
Text S1. Sequences of reference strains in the plasmids 713 
Text S2. Preparation protocol of HSV-1 and HSV-2 nucleocapsids 714 
Table 1. Intraassay variation 








 singleplex multiplex pMIXI singleplex multiplex pMIXI singleplex multiplex pMIXI 
10 1 33.2 ± 0.4 33.2 ± 0.4 33.1 ± 0.1 32.4 ± 0.7 32.4 ± 0.6 32.9 ± 0.6 32 ± 0.4 32.5 ± 0.3 32.1 ± 0.4 
10 2 30.3 ± 0.3 30.3 ± 0.3 30.5 ± 0.3 29.2 ± 0.2 29.1 ± 0.2 29.4 ± 0.3 28.9 ± 0.2 28.8 ± 0.2 28.7 ± 0.2 
10 3 26.9 ± 0.1 26.8 ± 0 26.9 ± 0.1 26.1 ± 0.3 25.8 ± 0.1 25.9 ± 0.1 25.7 ± 0.2 25.5 ± 0.1 25 ± 0.3 
10 4 23.4 ± 0.1 23.3 ± 0.1 23.5 ± 0.2 22.6 ± 0.2 22.6 ± 0.2 22.5 ± 0.2 22.1 ± 0.2 22.1 ± 0.2 22 ± 0.1 
10 5 20.1 ± 0.1 20.1 ± 0 20.3 ± 0.2 19.4 ± 0.4 19.2 ± 0.1 19.2 ± 0.1 18.8 ± 0.1 18.9 ± 0.4 18.8 ± 0.1 
10 6 16.9 ± 0.1 17.1 ± 0.2 16.8 ± 0.2 16.3 ± 0.2 16.1 ± 0.1 16 ± 0.2 15.8 ± 0.1 15.8 ± 0.2 15.6 ± 0.2 
Eff. % 100.1 101.7 100.3 101.0 101.7 100.5 103.2 100.9 100.7 
R
2 0.998 0.997 0.997 0.994 0.997 0.998 0.997 0.997 0.997 
Slope -3.32 -3.28 -3.32 -3.3 -3.28 -3.31 -3.25 -3.3 -3.31 




EBV   HCMV   KSHV 
 
 singleplex multiplex pMIXII singleplex multiplex pMIXII singleplex multiplex pMIXII 
10 1 32.6 ± 0.4 32.6 ± 0.5 32.6 ± 0.6 33.9 ± 0.4 33.5 ± 0.7 33.6 ± 0.4 33.6 ± 0.8 32.6 ± 0.8 32.9 ± 0.7 
10 2 29.0 ± 0.5 29.0 ± 0.2 29.1 ± 0.2 30.3 ± 0.3 30.4 ± 0.4 30.6 ± 0.3 29.4 ± 0.4 29.3 ± 0.5 28.9 ± 0.4 
10 3 25.6 ± 0.1 25.7 ± 0.1 25.5 ± 0.1 26.9 ± 0.1 26.9 ± 0.2 27.0 ± 0.3 25.8 ± 0.1 26.1 ± 0.2 25.7 ± 0.2 
10 4 22.3 ± 0.3 22.1 ± 0.1 22 ± 0.2 23.7 ± 0.1 23.6 ± 0.2 23.7 ± 0.2 22.6 ± 0.2 22.6 ± 0.2 22.4 ± 0.1 
10 5 18.9 ± 0.1 18.9 ± 0.2 18.8 ± 0.2 20.4 ± 0.2 20.3 ± 0.1 20.4 ± 0.1 19.3 ± 0.1 19.1 ± 0.1 19.0 ± 0.2 
10 6 15.7 ± 0.1 15.6 ± 0.1 15.5 ± 0.2 16.9 ± 0.1 16.8 ± 0.1 17.0 ± 0.1 16.1 ± 0.1 16 ± 0.1 15.5 ± 0.2 
Eff. % 97.8 99.5 98.6 98.2 98.4 99.7 95.9 98.9 97.2 
R
2 0.998 0.998 0.999 0.997 0.994 0.996 0.996 0.992 0.996 
Slope -3.37 -3.33 -3.36 -3.37 -3.36 -3.33 -3.42 -3.35 -3.39 




HHV-6A   HHV6-B   HHV-7 
 
 
singleplex multiplex pMIXIII singleplex multiplex pMIXIII singleplex multiplex pMIXIII 
10 1 32.4 ± 0.6 33.0 ± 0.4 33.3 ± 0.6 31.6 ± 0.9 31.8 ± 0.5 31.5 ± 0.5 31.5 ± 0.7 31.6 ± 0.7 32.2 ± 0.7 
10 2 29.5 ± 0.3 29.5 ± 0.4 29.6 ± 0.3 28.7 ± 0.4 28.6 ± 0.2 29.1 ± 0.3 28.1 ± 0.4 28.2 ± 0.4 28.3 ± 0.1 
10 3 26.1 ± 0.2 25.8 ± 0.1 26.1 ± 0.3 25.3 ± 0.1 25.3 ± 0.1 25.6 ± 0.2 25 ± 0.1 24.9 ± 0 25.0 ± 0.1 
10 4 22.7 ± 0.1 22.5 ± 0.1 22.9 ± 0.2 21.8 ± 0.2 22.0 ± 0.2 22.2 ± 0.1 21.6 ± 0.2 21.5 ± 0.1 21.5 ± 0.2 
10 5 19.2 ± 0.1 19.4 ± 0.2 19.6 ± 0.2 18.6 ± 0.1 18.8 ± 0.2 19 ± 0.2 18.1 ± 0.1 18.2 ± 0.1 18.4 ± 0.1 
10 6 16.3 ± 0.1 16.6 ± 0.1 16.1 ± 0.1 15.6 ± 0.1 15.7 ± 0.1 15.8 ± 0.1 15.0 ± 0.2 15.2 ± 0.1 15.1 ± 0.1 
Eff. % 100.6 100.2 98.2 100.3 103.8 101.9 100.7 102.7 98.2 
R
2 0.995 0.995 0.995 0.992 0.998 0.998 0.995 0.993 0.994 
Slope -3.31 -3.32 -3.37 -3.32 -3.23 -3.28 -3.31 -3.26 -3.37 
Interc. 38.3 38.4 38.7 37.6 37.4 37.7 37.01 36.9 37.5 
Table 2. Interassay variation 
                                                          Coefficient of Variation % 
copies/µl  HSV-1   HSV-2   VZV  
 singleplex multiplex pMIXI singleplex multiplex pMIXI singleplex multiplex pMIXI 
10 
1
 12 16 7 23 27 33 14 27 13 
10 
2
 21 20 12 12 10 8 6 9 16 
10 
3
 8 15 7 11 3 7 11 6 13 
10 
4
 4 7 4 9 2 9 4 8 2 
10 
5
 6 3 1 4 9 5 2 2 8 
10 
6
 7 4 10 9 6 3 5 9 7 
copies/µl  EBV   HCMV   KSHV  
 singleplex multiplex pMIXII singleplex multiplex pMIXII singleplex multiplex pMIXII 
10 
1
 24 23 20 15 14 16 15 14 16 
10 
2
 11 4 7 13 9 8 13 9 8 
10 
3
 11 10 4 9 6 5 9 6 5 
10 
4
 12 1 12 11 2 7 11 2 7 
10 
5
 11 2 4 18 3 12 18 3 12 
10 
6
 7 4 14 10 6 3 10 6 3 
copies/µl  HHV-6A   HHV6-B   HHV-7  
 singleplex multiplex pMIXIII singleplex multiplex pMIXIII singleplex multiplex pMIXIII 
10 
1
 15 4 20 27 28 19 19 25 31 
10 
2
 7 19 7 22 13 5 10 4 14 
10 
3
 14 9 7 13 3 6 11 9 12 
10 
4
 9 3 6 4 12 10 9 10 3 
10 
5
 3 1 2 3 3 6 8 2 4 
10 
6
 12 15 0 6 11 4 3 8 14 
 
 
Table 3.Pre-quantified reference material for HHV-DNA quantification 
 









































VZV Quantified DNA, 
ATCC 




qPCR, (NIBSC code 
09/260), (57) 




qPCR, (NIBSC code 
09/162) (58) 
Merlin GU179001.1 1.0E4 3.2E4 3.2 0.51 
KSHV Genome in BAC Spectrophotometer BAC16 
JSC-1 














qPCR, (NIBSC code 
15/266, (59)  
Z29 AF157706.1 1.1E5 1.8E5 1.6 0.20 
HHV-7 Spiked serum, 
HHV-6 
Foundation 







Table 4. Clinical samples and other sample material 
Clinical samples Other sample material 












rapid viral culture 
immunoperoxidase, 








strain F KM222724.1 
HSV-2 mucocutaneous 
swab 
rapid viral culture 
immunoperoxidase, 















EIA, qPCR(4, 31, 61)   20/20 







EBV Plasma 46 EBV (GeneProof 
Epstein-Barr Virus 










HCMV Plasma 48 GeneProof 
Cytomegalovirus 







































































On the left are the estimated genome copies per dilution and on the right the copy numbers/µl of DNA extract quantified 
by HERQ-9. In parentheses are the coefficient of variations (CV %) between the estimated and measured copy numbers. 
Estimated and measured viral genome copies showed significant correlation (pearson’s r = 0.996, p<0.01). 
Table 5. Three viral genomes intermixed into the same reaction.  
 
 Estimated viral genome copies/µl          Measured viral genome copies/µl 
Virus mix HSV-1 HSV-2 VZV HSV-1 HSV-2 VZV 
1 1.1E+06 5.6E+03 2.8E+02 1.2E+06 (6) 1.0E+04 (42) 1.9E+02 (28) 
2 1.3E+04 5.9E+04 3.4E+01 1.3E+04 (1) 6.3E+04 (4) 1.4E+01 (57) 
3 1.2E+03 6.2E+03 4.2E+04 1.1E+03 (9) 5.1E+03 (13) 2.7E+04 (29) 
4 1.2E+02 4.5E+01 4.2E+03 1.1E+02 (9) 7.2E+01 (33) 3.3E+03 (15) 
5 1.1E+05 4.6E+01 3.6E+04 1.1E+05 (2)  8.9E+01 (45) 3.0E+04 (13) 
6 1.2E+02 5.9E+04 4.2E+04 1.6E+02 (18) 4.9E+04 (13) 4.2E+04 (1) 
Virus mix EBV HCMV KSHV EBV HCMV KSHV 
7 1.1E+05  1.5E+03  5.4E+03 1.2E+05 (5) 2.6E+03 (37) 6.7E+03 (15) 
8 1.1E+04  1.7E+05  4.9E+05 1.3E+04 (12) 1.8E+05 (4) 6.4E+05 (20) 
9 1.2E+03  1.8E+04  5.7E+04 1.4E+03 (10) 1.5E+04 (11) 6.9E+04 (14) 
10 7.1E+01  1.3E+02 6.0E+05 1.1E+02 (31) 1.9E+02 (26) 6.2E+05 (2) 
11 1.1E+05  1.7E+05  4.1E+02 1.2E+05 (6) 2.0E+05 (12) 9.7E+02 (57) 
12 9.6E+01  1.8E+04  5.7E+04 1.3E+02 (22) 1.5E+04 (14) 5.4E+04 (3) 
Virus mix HHV6-A HHV6-B HHV-7 HHV6-A HHV6-B HHV-7 
13 1.9E+03 6.2E+03 1.0E+02 1.7E+03 (9) 7.1E+03 (9) 1.3E+02 (24) 
14 1.9E+03 6.1E+02 1.0E+02 1.7E+03 (10) 4.6E+02 (18) 1.1E+02 (10) 
15 9.3E+01 6.1E+03 5.2E+01 1.2E+02 (21) 5.6E+03 (6) 3.6E+01 (25) 
16 1.3E+03 6.1E+01 5.2E+01 1.4E+03 (9) 1.2E+02 (47) 3.6E+01 (26) 
17 4.5E+00 7.9E+01 1.0E+02 1.1E+01 (58) 5.2E+01 (30) 1.1E+02 (4) 
18 1.3E+03 6.1E+03 5.2E+01 1.9E+03 (27) 1.1E+04 (40) 4.9E+01 (4) 
 
Table 6. Primers and probes 
* Nucleotides in [] refer to locked nucleic acids. 
Virus  Oligo name Concentration 
 
Sequence 5’ – 3’ Position of the 








HSV-1 HSV-1 FWDLP1 








































































H5 rev 211 
















HHV8 fwd 3.1  
HHV8 REV 10 
H8 Probe 300 
 
 













HHV6A FWD1-3  
HHV6A REV 10 
HHV6A LNA Probe A1 
HHV6A LNA Probe A2 
 
 
















H6B ROTY 1  













(83 bp)  
U90 AB021506.1 
HHV-7  
HHV7 1. FWD 
HHV7 1. REV 
H7 MOP PROBE 
 
 
400 nM 
400 nM 
300 nM 
 
 
CTCGCAGATTGCTTGTTG 
GCATACACCAACCCTACTGTAA 
[TxRd]TTAGGCATCACGTTGGCATTG[BHQ2] 
 
 
88332-88490 
(159 bp) 
U57 AF037218.1 












